Skip to main content
SpringerLink
Log in

Ethical Issues for Clinical Studies That use Human Embryonic Stem Cells: The 2014 Revisions to the Japanese Guidelines

  • Published:
Stem Cell Reviews and Reports Aims and scope Submit manuscript

Abstract

The use of human embryonic stem cells (hESCs) in clinical studies has been expanding in recent years. The application of hESCs in clinical studies raises ethical issues from a different standpoint compared with the use of other types of stem cells. In Japan, the Guidelines on the Derivation of Human Embryonic Stem Cells, and Guidelines on the Distribution and Utilization of Human Embryonic Stem Cells had been revised for clinical studies in 2014. In the revised guidelines, the method for protection of personal information was changed to offer the choice between unlinkable anonymization and linkable anonymization, to enable the use of information on diseases suffered by donors and the assurance of traceability for safety. Procedures for re-consent are generally prohibited out of consideration for donors’ feelings. However, obtaining re-consent is permitted when consent for re-consent has been received in advance and approval has been given by an ethical review board, in which case the donors may be contacted. Incidental findings obtained from hESCs are not disclosed individually to donors, while the research results should be actively published for the common good. These guidelines have enabled the derivation, distribution, and use of hESCs for clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ben-David, U., Kopper, O., & Benvenisty, N. (2012). Expanding the boundaries of embryonic stem cells. Cell Stem Cell, 10(6), 666–677.

    Article  CAS  PubMed  Google Scholar 

  2. Schwartz, S. D., Hubschman, J. P., Heilwell, G., et al. (2012). Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet, 379, 713–720.

    Article  CAS  PubMed  Google Scholar 

  3. Schwartz, S. D., Regillo, C. D., Lam, B. L., et al. (2015). Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet, 385, 509–516.

    Article  PubMed  Google Scholar 

  4. Song, W. K., Park, K. M., Kim, H. J., et al. (2015). Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in asian patients. Stem Cell Reports, 4(5), 860–872.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Council for Science, Technology and Policy (2004) Basic Ideas on the Handling of Human Embryos. http://www8.cao.go.jp/cstp/tyousakai/life/haihu39/siryo5-1-1.pdf (in Japanese).

  6. Hug, K., Hermerén, G. (2011) Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Reviews, 7(4), 761–774.

  7. Isasi, R. M. (2009). Policy interoperability in stem cell research: demystifying harmonization. Stem Cell Reviews, 5(2), 108–115.

    Article  PubMed  Google Scholar 

  8. Guidelines on the Derivation of Human Embryonic Stem Cells (revised in 2014) http://www.lifescience.mext.go.jp/files/pdf/n1430_01.pdf (in Japanese, English version is under construction).

  9. Guidelines on the Distribution and Utilization of Human Embryonic Stem Cells (revised in 2014) http://www.lifescience.mext.go.jp/files/pdf/n1460_01.pdf (in Japanese, English version is under construction).

  10. The Act on the Safety of Regenerative Medicine http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000030847.pdf (in Japanese).

  11. The Pharmaceuticals, Medical Devices and Other Therapeutic Products Act.

  12. Konomi, K., Tobita, M., Kimura, K., & Sato, D. (2015). New Japanese initiatives on stem cell therapies. Cell Stem Cell, 16(4), 350–352.

    Article  CAS  PubMed  Google Scholar 

  13. Ministerial ordinance of the act on the safety of regenerative medicine. (2014). http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000065532.pdf (in Japanese).

  14. Isasi, R., Andrews, P. W., Baltz, J. M., et al. (2014). Identifiability and privacy in pluripotent stem cell research. Cell Stem Cell, 14(4), 427–430.

    Article  CAS  PubMed  Google Scholar 

  15. Wadman, M. (2010). Most popular cell lines close to approval for US federal funding. Nature, 464, 967.

    Article  CAS  PubMed  Google Scholar 

  16. Kawakami, M., Sipp, D., & Kato, K. (2010). Regulatory impacts on stem cell research in Japan. Cell Stem Cell, 6(5), 415–418.

    Article  CAS  PubMed  Google Scholar 

  17. The Expert Committee on Bioethics 85th minutes (2014) http://www8.cao.go.jp/cstp/tyousakai/life/haihu86/siryo1.pdf (in Japanese).

  18. The International Society for Stem Cell Research (ISSCR) (2006) Guidelines for the Conduct of Human Embryonic Stem Cell Research http://www.isscr.org/docs/default-source/hesc-guidelines/isscrhescguidelines2006.pdf.

  19. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada (2014) Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans http://www.pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/Default/.

  20. The Presidential Commission for the Study of Bioethical Issues (2013) Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts. http://bioethics.gov/sites/default/files/FINALAnticipateCommunicate_PCSBI_0.pdf.

  21. Green, R. C., Berg, J. S., Grody, W., W, et al. (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine 15(7), 565–574.

  22. Isasi, R., Knoppers, B. M., Andrews, P. W., et al. (2012). Disclosure and management of research findings in stem cell research and banking: policy statement. Regenerative Medicine, 7(3), 439–448.

    Article  CAS  PubMed  Google Scholar 

  23. Lomax, G. P., & Shepard, K. A. (2013). Return of results in translational iPS cell research: considerations for donor informed consent. Stem Cell Research and Therapy, 4(1), 6.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Guidance for Guidelines on the Distribution and Utilization of Human Embryonic Stem Cells (2015) http://www.lifescience.mext.go.jp/files/pdf/n1485_01r5.pdf (in Japanese).

Download references

Acknowledgments

The author is grateful to the members and the secretariat of the Expert Panel on Bioethics of the Council for Science, Technology and Innovation in the Cabinet Office of Japan.

Conflict of Interest

The author declares no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Agrogenomics Research Center, National Institute of Agrobiological Sciences, Tsukuba, 305-8602, Japan

    Hiroshi Mizuno

Authors
  1. Hiroshi Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Mizuno.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mizuno, H. Ethical Issues for Clinical Studies That use Human Embryonic Stem Cells: The 2014 Revisions to the Japanese Guidelines. Stem Cell Rev and Rep 11, 676–680 (2015). https://doi.org/10.1007/s12015-015-9607-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-015-9607-7

Keywords

Search

Navigation